TW584563B - Parenteral formulation - Google Patents

Parenteral formulation Download PDF

Info

Publication number
TW584563B
TW584563B TW087115501A TW87115501A TW584563B TW 584563 B TW584563 B TW 584563B TW 087115501 A TW087115501 A TW 087115501A TW 87115501 A TW87115501 A TW 87115501A TW 584563 B TW584563 B TW 584563B
Authority
TW
Taiwan
Prior art keywords
water
compound
parenteral
parenteral formulation
formulation
Prior art date
Application number
TW087115501A
Other languages
English (en)
Chinese (zh)
Inventor
Hoogevest Peter Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW584563B publication Critical patent/TW584563B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW087115501A 1997-10-09 1998-09-17 Parenteral formulation TW584563B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721497.7A GB9721497D0 (en) 1997-10-09 1997-10-09 Organic compounds

Publications (1)

Publication Number Publication Date
TW584563B true TW584563B (en) 2004-04-21

Family

ID=10820342

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087115501A TW584563B (en) 1997-10-09 1998-09-17 Parenteral formulation

Country Status (31)

Country Link
US (2) US6316417B1 (enExample)
EP (1) EP1033988B1 (enExample)
JP (2) JP2001519395A (enExample)
KR (1) KR100760326B1 (enExample)
CN (1) CN1210032C (enExample)
AR (1) AR015465A1 (enExample)
AT (1) ATE257383T1 (enExample)
AU (1) AU748034B2 (enExample)
BR (1) BR9812861A (enExample)
CA (1) CA2304661C (enExample)
CO (2) CO4950520A1 (enExample)
CZ (1) CZ298900B6 (enExample)
DE (1) DE69821024T2 (enExample)
DK (1) DK1033988T3 (enExample)
ES (1) ES2214738T3 (enExample)
GB (1) GB9721497D0 (enExample)
HU (1) HU226106B1 (enExample)
ID (1) ID24134A (enExample)
IL (1) IL135123A0 (enExample)
MY (1) MY122129A (enExample)
NO (1) NO327263B1 (enExample)
NZ (1) NZ503526A (enExample)
PE (1) PE121998A1 (enExample)
PL (1) PL192287B1 (enExample)
PT (1) PT1033988E (enExample)
RU (1) RU2242231C2 (enExample)
SK (1) SK286253B6 (enExample)
TR (1) TR200000870T2 (enExample)
TW (1) TW584563B (enExample)
WO (1) WO1999018966A1 (enExample)
ZA (1) ZA989183B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101711739B (zh) * 2008-10-08 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 卡马西平的口服药物组合物
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
ES2081965T3 (es) * 1989-12-27 1996-03-16 Ciba Geigy Ag Dispositivo para homogenizar la distribuccion no homogenea de la luz de un haz de rayos laser.
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
RU2020972C1 (ru) * 1991-02-07 1994-10-15 Мегдятов Рашид Салехович Способ лечения невралгии тройничного нерва
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Also Published As

Publication number Publication date
US6316417B1 (en) 2001-11-13
RU2242231C2 (ru) 2004-12-20
PT1033988E (pt) 2004-05-31
HUP0004362A3 (en) 2006-06-28
KR20010072533A (ko) 2001-07-31
ES2214738T3 (es) 2004-09-16
CA2304661C (en) 2007-12-11
SK5052000A3 (en) 2000-12-11
PL339446A1 (en) 2000-12-18
PE121998A1 (es) 1999-12-08
BR9812861A (pt) 2000-08-08
ID24134A (id) 2000-07-06
NO20001730L (no) 2000-04-04
SK286253B6 (sk) 2008-06-06
EP1033988A1 (en) 2000-09-13
KR100760326B1 (ko) 2007-09-20
CZ298900B6 (cs) 2008-03-05
DE69821024T2 (de) 2004-10-28
CO4950520A1 (es) 2000-09-01
HK1031824A1 (en) 2001-06-29
NO20001730D0 (no) 2000-04-04
AR015465A1 (es) 2001-05-02
HU226106B1 (en) 2008-04-28
ZA989183B (en) 1999-04-09
CN1210032C (zh) 2005-07-13
GB9721497D0 (en) 1997-12-10
JP2005281314A (ja) 2005-10-13
CO5090854A1 (es) 2001-10-30
NZ503526A (en) 2003-01-31
IL135123A0 (en) 2001-05-20
EP1033988B1 (en) 2004-01-07
HUP0004362A2 (hu) 2001-08-28
US20020055503A1 (en) 2002-05-09
DK1033988T3 (da) 2004-04-13
DE69821024D1 (de) 2004-02-12
CA2304661A1 (en) 1999-04-22
ATE257383T1 (de) 2004-01-15
NO327263B1 (no) 2009-05-25
PL192287B1 (pl) 2006-09-29
MY122129A (en) 2006-03-31
US6458770B1 (en) 2002-10-01
TR200000870T2 (tr) 2000-10-23
CN1274286A (zh) 2000-11-22
AU9629898A (en) 1999-05-03
AU748034B2 (en) 2002-05-30
CZ20001279A3 (cs) 2000-07-12
WO1999018966A1 (en) 1999-04-22
JP2001519395A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
JP2018184433A (ja) 酢酸グラチラマーの製造方法
MXPA04003927A (es) Una solucion de inhalacion de albuterol e ipratropio, sistema, equipo y metodo para aliviar sintomas de enfermedad pulmonar obstructiva cronica.
US9532947B2 (en) Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules
RU2621144C2 (ru) Лекарственная форма гемцитабина большого объема для инфузии и комплект, включающий лекарственную форму
CN1332662C (zh) 左旋奥硝唑的静脉给药制剂及其制备方法
KR102246136B1 (ko) 산화-민감성 제형을 위한 안정한 즉석 사용식 주입 백을 제조하는 방법
WO2009047634A2 (en) Aqueous formulations of acetaminophen for injection
US6458770B1 (en) Parenteral formulations comprising carbamazepine or its derivatives
TW200526195A (en) Compositions comprising cyclohexylamines and aminoadamantanes
CN100455286C (zh) 帕洛诺司琼注射液及其制备方法
AU2018332212B2 (en) Topical formulations of chloroprocaine
EP3893840B1 (en) Pharmaceutical compositions for parenteral administration comprising ibuprofen and a phosphate buffer
US20240115579A1 (en) Pharmaceutical compositions and manufacturing methods thereof
MXPA00003413A (en) Parenteral formulations comprising carbamazepine or its derivatives
WO2007069070A2 (en) Aseptically filled multidose injectable dosage forms of granisetron
OA19516A (en) Topical formulations of Chloroprocaine.
HK1031824B (en) Parenteral formulations comprising 10-hydroxy-10, 11-tetrahydrocarbamazepine, water and glucose
CN101252910A (zh) 内-n-(9-甲基-9-氮杂双环[3.3.1]壬-3-基)-1-甲基-1h-吲唑-3-甲酰胺盐酸盐的药物制剂

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees